Stay updated on Efgartigimod SubQ in Idiopathic Inflammatory Myopathy Clinical Trial

Sign up to get notified when there's something new on the Efgartigimod SubQ in Idiopathic Inflammatory Myopathy Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Efgartigimod SubQ in Idiopathic Inflammatory Myopathy Clinical Trial page

  1. Check
    7 days ago
    Change Detected
    Summary
    A site-wide NIH notice about using “Super Intelligence” in place of “Artificial Intelligence” appears above the unchanged 403 error page.
    Difference
    1%
    Check dated 2026-10-24T18:49:22.000Z thumbnail image
  2. Check
    14 days ago
    Change Detected
    Summary
    The footer revision identifier changes from v3.7.1 to v3.7.2 on the ClinicalTrials.gov 403 Forbidden page.
    Difference
    0.2%
    Check dated 2026-10-17T18:24:25.000Z thumbnail image
  3. Check
    21 days ago
    Change Detected
    Summary
    The ClinicalTrials.gov page footer now displays revision v3.7.1 instead of v3.7.0.
    Difference
    0.2%
    Check dated 2026-10-10T19:12:58.000Z thumbnail image
  4. Check
    42 days ago
    Change Detected
    Summary
    The page now shows a 403 Forbidden error instead of the study record content, replacing the study details and navigation with an access-denied screen. This blocks access to the essential information the page is intended to present.
    Difference
    17%
    Check dated 2026-09-19T18:46:23.000Z thumbnail image
  5. Check
    63 days ago
    Change Detected
    Summary
    Page revision updated from v3.6.5 to v3.6.6, indicating a maintenance update to the study details page. No study content changes are indicated beyond the revision label.
    Difference
    0.0%
    Check dated 2026-08-29T19:36:24.000Z thumbnail image
  6. Check
    77 days ago
    Change Detected
    Summary
    The page transitioned from an error screen to the complete Study Details for NCT05979441, incorporating regulatory information, IPD plans, MeSH terms, study design/outcomes, and the 92 participating locations.
    Difference
    85%
    Check dated 2026-08-15T19:08:39.000Z thumbnail image

Stay in the know with updates to Efgartigimod SubQ in Idiopathic Inflammatory Myopathy Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Efgartigimod SubQ in Idiopathic Inflammatory Myopathy Clinical Trial page.